Patricia Weiser, Pharm.D.

Researchers have been working on sorting out the causal direction of multiple sclerosis (MS) and depression. These findings suggest that depression can be a consequences of MS-related disability not the other way around.

Mutations in one locus were associated with a decrease in the median time until needing a walking aid of between 3.3 and 3.7 years.

70% of inflammatory bowel disease patients managed by in-system specialty pharmacies were adherent to their therapies, according to research findings.

Results reported in the New England Journal of Medicine show that the Eli Lilly drug was superior to placebo in keeping ulcerative colitis in remission.

The researchers conclude that it is “reasonable option” for older patients with stable multiple sclerosis (MS) to stop taking disease-modifying therapy because the risk of relapse from doing so is small.

The favorable results from the 84-patient study may, in part, depend on some of the definitions used.